{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:56:58Z","timestamp":1789376218519,"version":"build-2803163510"},"reference-count":90,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.cjca.2014.04.029","type":"journal-article","created":{"date-parts":[[2014,5,4]],"date-time":"2014-05-04T20:02:43Z","timestamp":1399233763000},"page":"869-878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management"],"prefix":"10.1016","volume":"30","author":[{"given":"Judy","family":"Truong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Cramarossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2014.04.029_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10549-009-0730-5","article-title":"Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy","volume":"122","author":"Blaes","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cjca.2014.04.029_bib2","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","article-title":"American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects","volume":"25","author":"Carver","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib3","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms1601","article-title":"BRCA1 is an essential regulator of heart function and survival following myocardial infarction","volume":"2","author":"Shukla","year":"2011","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2014.04.029_bib5","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.029_bib6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pharmthera.2009.10.002","article-title":"Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy","volume":"125","author":"Raschi","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cjca.2014.04.029_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12156-010-0058-8","article-title":"Drug-induced QT interval prolongation in cancer patients","volume":"4","author":"Becker","year":"2010","journal-title":"Oncol Rev"},{"key":"10.1016\/j.cjca.2014.04.029_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","article-title":"Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjca.2014.04.029_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib10","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","article-title":"Molecularly targeted oncology therapeutics and prolongation of the QT interval","volume":"25","author":"Strevel","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib11","unstructured":"BC Cancer Agency. Drug Index (Professional). Available at: www.bccancer.bc.ca\/HPI\/DrugDatabase\/DrugIndexPro\/default.htm. Accessed October 26,\u00a02013."},{"key":"10.1016\/j.cjca.2014.04.029_bib12","unstructured":"Cancer Care Ontario. Drug Formulary. Available at: www.cancercare.on.ca\/toolbox\/drugs\/drugformulary. Accessed October 26,\u00a02013."},{"key":"10.1016\/j.cjca.2014.04.029_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.029_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3747\/co.v18i6.968","article-title":"First annual Canadian Cardiac Oncology Network conference","volume":"18","author":"Dent","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib15","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","article-title":"Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group","volume":"15","author":"Mackey","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/157340311799960681","article-title":"Management of chemotherapy induced cardiomyopathy","volume":"7","author":"Saidi","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.cjca.2014.04.029_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cjca.2014.04.029_bib19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cjca.2014.04.029_bib20","series-title":"UpToDate","article-title":"Cardiotoxicity of anthracycline-like chemotherapy agents","author":"Floyd","year":"2013"},{"key":"10.1016\/j.cjca.2014.04.029_bib21","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2014.04.029_bib22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies","volume":"131","author":"Wouters","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2014.04.029_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2013.02.007","article-title":"State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review","volume":"88","author":"Berardi","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cjca.2014.04.029_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12350-013-9707-1","article-title":"Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively","volume":"20","author":"Schwartz","year":"2013","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11886-013-0362-6","article-title":"Cardiac toxicity of anticancer agents","volume":"15","author":"Colombo","year":"2013","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cjca.2014.04.029_bib26","first-page":"395","article-title":"Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies","volume":"32","author":"Adao","year":"2013","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1753944712474332","article-title":"Chemotherapy-related cardiotoxicity","volume":"7","author":"Aggarwal","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2014.04.029_bib28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.seminoncol.2013.01.004","article-title":"Cardiovascular toxicities of cancer chemotherapy","volume":"40","author":"Bonita","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib29","first-page":"59","article-title":"Chemotherapy-induced cardiotoxicity","volume":"8","author":"Florescu","year":"2013","journal-title":"Maedica (Buchar)"},{"key":"10.1016\/j.cjca.2014.04.029_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.seminoncol.2013.01.002","article-title":"Cardiovascular toxicities of biological therapies","volume":"40","author":"Ryberg","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/157340311799960636","article-title":"Cardiotoxicity of molecularly targeted agents","volume":"7","author":"Hedhli","year":"2011","journal-title":"Curr Cardiol Rev"},{"issue":"Suppl 7","key":"10.1016\/j.cjca.2014.04.029_bib32","doi-asserted-by":"crossref","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib33","doi-asserted-by":"crossref","first-page":"487.e1","DOI":"10.1016\/j.ahj.2010.05.037","article-title":"Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment","volume":"160","author":"Cadeddu","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2014.04.029_bib34","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3892\/etm.2011.305","article-title":"Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction","volume":"2","author":"Dessi","year":"2011","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.cjca.2014.04.029_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/2193-1801-2-198","article-title":"Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on epirubin-induced inflammation and oxidative stress assessed by serial strain rate","volume":"2","author":"Dessi","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.cjca.2014.04.029_bib36","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2014.04.029_bib37","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cardfail.2012.06.416","article-title":"Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia","volume":"18","author":"El-Shitany","year":"2012","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2014.04.029_bib38","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib39","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2014.04.029_bib41","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib42","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cjca.2014.04.029_bib43","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/heartjnl-2012-303151","article-title":"Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors","volume":"99","author":"Farolfi","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2014.04.029_bib44","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1634\/theoncologist.2011-0445","article-title":"Administration of angiotensin-converting enzyme inhibitors and beta-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?","volume":"17","author":"Oliva","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.cjca.2014.04.029_bib45","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","article-title":"Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy","volume":"135","author":"Wilop","year":"2009","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib46","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.029_bib47","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2002.12.102","article-title":"Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer","volume":"20","author":"Lipshultz","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib48","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2004.06.022","article-title":"Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines","volume":"22","author":"Silber","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib49","first-page":"115","article-title":"Beta-blockade in adriamycin-induced cardiomyopathy","volume":"6","author":"Noori","year":"2000","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2014.04.029_bib50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib51","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.healun.2004.12.108","article-title":"Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure","volume":"24","author":"Tallaj","year":"2005","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2014.04.029_bib52","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib53","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.seminoncol.2013.01.008","article-title":"Strategies to prevent and treat cardiovascular risk in cancer patients","volume":"40","author":"Cardinale","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib54","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines","volume":"21","author":"Bovelli","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib55","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1200\/JCO.2004.11.032","article-title":"Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline","volume":"22","author":"Landier","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib56","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib57","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s11936-013-0248-3","article-title":"Managing cardiotoxicity of chemotherapy","volume":"15","author":"Colombo","year":"2013","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.cjca.2014.04.029_bib58","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/CIRCULATIONAHA.112.100560","article-title":"Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues","volume":"126","author":"Khouri","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.029_bib59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1532-429X-10-5","article-title":"Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy","volume":"10","author":"Fallah-Rad","year":"2008","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.cjca.2014.04.029_bib60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12410-012-9163-3","article-title":"Assessing the cardiac toxicity of chemotherapeutic agents: role of echocardiography","volume":"5","author":"Tan","year":"2012","journal-title":"Curr Cardiovasc Imaging Rep"},{"key":"10.1016\/j.cjca.2014.04.029_bib61","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib62","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2008.12.014","volume":"53","author":"Rautaharju","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib63","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ahj.2009.05.031","article-title":"Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab","volume":"158","author":"Hare","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2014.04.029_bib64","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2014.04.029_bib65","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib66","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/echo.12179","article-title":"Tissue doppler myocardial velocity imaging in infants and children\u2014a window into developmental changes of myocardial mechanics","volume":"30","author":"Pauliks","year":"2013","journal-title":"Echocardiography"},{"key":"10.1016\/j.cjca.2014.04.029_bib67","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jacc.2013.10.060","article-title":"Cardiac biomarkers, cardiotoxicity, and active collaboration: is this the final frontier or the wave we should catch?","volume":"63","author":"Lenihan","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib68","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.04.029_bib69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/ajco.12085","article-title":"Early detection of treatment induced cardiac toxicity - can we do better?","volume":"9","author":"Lombard","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib70","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cjca.2014.04.029_bib72","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cjca.2014.04.029_bib73","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1161\/CIRCULATIONAHA.105.167586","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.029_bib74","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cjca.2012.10.007","article-title":"The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure","volume":"29","author":"McKelvie","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib75","first-page":"1073","article-title":"The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor","volume":"7","author":"Yoshiji","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2014.04.029_bib76","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review","volume":"23","author":"Mc Menamin","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.cjca.2014.04.029_bib77","first-page":"549","article-title":"Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes","volume":"4","author":"Chae","year":"2013","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.cjca.2014.04.029_bib78","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ijc.27576","article-title":"Cardiovascular medications in angiogenesis\u2013how to avoid the sting in the tail","volume":"131","author":"Ma","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cjca.2014.04.029_bib79","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/fca.12.44","article-title":"Cardiotoxicity in childhood cancer survivors: strategies for prevention and management","volume":"8","author":"Harake","year":"2012","journal-title":"Future Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib80","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib81","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib82","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jacc.2007.06.037","article-title":"Early breast cancer therapy and cardiovascular injury","volume":"50","author":"Jones","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.029_bib83","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S1470-2045(09)70031-2","article-title":"Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction","volume":"10","author":"Jones","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib84","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2003.04.093","article-title":"Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes","volume":"21","author":"Courneya","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cjca.2014.04.029_bib85","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bbi.2005.04.001","article-title":"Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial","volume":"19","author":"Fairey","year":"2005","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.cjca.2014.04.029_bib86","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1503\/cmaj.051073","article-title":"Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis","volume":"175","author":"McNeely","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2014.04.029_bib87","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/CIRCULATIONAHA.111.021774","article-title":"Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms","volume":"124","author":"Scott","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.029_bib88","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1158\/1078-0432.CCR-09-0628","article-title":"Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training","volume":"15","author":"Haykowsky","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"Suppl 26","key":"10.1016\/j.cjca.2014.04.029_bib89","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/jco.2013.31.26_suppl.128","article-title":"Impact of physician and center case volume on the adequacy of cardiac monitoring during adjuvant trastuzumab in breast cancer (abstract)","volume":"31","author":"Kumachev","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 26","key":"10.1016\/j.cjca.2014.04.029_bib90","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1200\/jco.2013.31.15_suppl.6625","article-title":"Impact of center case volume on cardiotoxicity during adjuvant trastuzumab in breast cancer (abstract)","volume":"31","author":"Chin-Yee","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14003158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14003158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T20:30:37Z","timestamp":1597782637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X14003158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":90,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0828282X14003158"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2014.04.029","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2014.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}